Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.

AbstractObjective:The aim of this study was to establish the gynecological effects of 5 years of treatment with lasofoxifene versus placebo in postmenopausal osteoporotic women.Methods:A total of 8,556 women aged 59 to 80 years with femoral neck or spine bone mineral density T scores of −2.5 or lowe